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Abstract
Mammographic density reflects the amount of stromal and epithelial tissues in relation to adipose 
tissue in the breast and is a strong risk factor for breast cancer. Here we report the results from 
meta-analysis of genome-wide association studies (GWAS) of three mammographic density 
phenotypes: dense area, non-dense area and percent density in up to 7,916 women in stage 1 and 
an additional 10,379 women in stage 2. We identify genome-wide significant (P<5×10−8) loci for 
dense area (AREG, ESR1, ZNF365, LSP1/TNNT3, IGF1, TMEM184B, SGSM3/MKL1), non-
dense area (8p11.23) and percent density (PRDM6, 8p11.23, TMEM184B). Four of these regions 
are known breast cancer susceptibility loci, and four additional regions were found to be 
associated with breast cancer (P<0.05) in a large meta-analysis. These results provide further 
evidence of a shared genetic basis between mammographic density and breast cancer and illustrate 
the power of studying intermediate quantitative phenotypes to identify putative disease 
susceptibility loci.
INTRODUCTION
Variations in the appearance of the mammogram reflect differences in breast fibroglandular 
tissue that appears white or radio-dense, and fat that appears black or non-dense. After 
adjustment for age and body mass index (BMI), the proportion of the total breast area that is 
dense (percent density (PD)) is a strong risk factor for breast cancer1, and both dense (DA) 
and non-dense areas (NDA), are also independently associated with breast cancer risk2,3. 
PD, DA and NDA are all highly heritable (0.6–0.7)4,5, but to date few genetic loci 
associated with mammographic density have been identified6–8.
Here we report results from a two-stage (discovery and replication stages) GWAS of DA, 
NDA and PD, respectively. We identify genome-wide significant (P<5×10−8) loci for dense 
area (AREG, ESR1, ZNF365, LSP1/TNNT3, IGF1, TMEM184B and SGSM3/MKL1), non-
dense area (8p11.23) and percent density (PRDM6, 8p11.23, TMEM184B). Our results add 
to the growing body of evidence that mammographic density and breast cancer risk share a 
genetic component.
RESULTS
Our discovery phase included eleven studies with GWAS data (Methods, Supplementary 
Note 1) comprising a total of 7,916 women. Study subjects were predominantly post-
menopausal women of European ancestry participating in the Markers of Density (MODE) 
consortium. Mammographic density was measured using CUMULUS9 (Supplementary 
Table 1) and 1,642 (21%) of the subjects were breast cancer cases. All studies were imputed 
to HapMap phase II before meta-analysis (Supplementary Table 2). For each SNP, we 
combined study-specific p-values and direction of association using the METAL software10. 
We assessed 200 promising SNPs for replication in up to 10,379 women from eleven 
different studies (Supplementary Table 3, Supplementary Note 2).
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For DA (n=7,600), no SNP reached genome-wide significance in the discovery phase 
(Supplementary Figs. 1 and 2). However, through replication analysis (Supplementary Table 
4), we identified seven independent loci significantly associated (P<5×10−8) with DA 
(Table 1, Supplementary Figs. 3 and 4) including AREG, ESR1, ZNF365, LSP1/TNNT3, 
IGF1, TMEM184B and SGSM3/MKL1.
The AREG gene is a member of the epidermal growth factor family that promotes growth of 
normal epithelial cells and variants strongly correlated with our top SNP rs10034692 in this 
region have previously been associated with breast size11. Although we observed the 
strongest association for rs10034692, another SNP (rs12642133) located 116kb away and in 
weak linkage disequilibrium (LD) with rs10034692 (r-sq=0.16, D’=1.00) also reached 
genome-wide significance (Supplementary Table 4). We investigated these two SNPs 
further in 6,624 women from the NHS, BBCC, MCBCS and MMHS studies for whom we 
had individual-level genotype data. Both SNPs were associated with DA in this dataset 
when analyzed separately (β=−0.16, P=0.0002 for rs10034692 and β=0.17, P=9×10−6 for 
rs12642133). Including both SNPs in the same model attenuated the signal for both SNPs 
(β=−0.10, P=0.04 for rs10034692 and β=0.13, P=0.002 for rs12642133). Thus, it is possible 
that these two SNPs are either a proxy for another yet unidentified causal SNP or that they 
represent two independent causal SNPs. Interestingly, rs12642133 is located in a weak 
enhancer region in human mammary epithelial cells (HMEC).
SNPs in ESR1 have earlier been associated with breast cancer risk12−15 and rs12665607 
identified here is in strong LD with the breast cancer SNP rs3757318 (r-sq=0.87, D’=1.00) 
and in moderate LD with SNPs previously associated with breast size11.
The rs10995190 SNP in the ZNF365 region has been associated with both PD6 and breast 
cancer risk14 but this is the first time it has been found to be associated with DA specifically. 
We observed multiple SNPs in the ZNF365 gene associated with DA and since multiple 
independent SNPs in ZNF365 are associated with breast cancer14,16, we conducted 
conditional analyses to identify potential independent signals. In particular, SNPs rs1949359 
(r-sq=0.08, D’=0.36 with rs10995190) and rs10733779 (r-sq=0.11, D’=1.00 with 
rs10995190) showed genome-wide significant associations with DA. After adjusting for 
rs10995190, the associations for both rs1949359 (P=4.4×10−5 before and P=0.008 after 
adjustment) and rs10733779 (P=1.9×10−6 before and P=0.002 after adjustment) were 
attenuated. Additional analyses in larger datasets will be necessary to determine if there are 
multiple independent SNPs in this region.
We identified a rare (minor allele frequency (MAF)=0.02) SNP 222 kb upstream of IGF1 
that was associated with DA. IGF1 is a candidate gene for breast cancer risk17 and is 
hypothesized to be involved in breast development. Indeed, circulating levels of IGF-1 are 
associated with breast cancer risk18.
We also confirmed previous findings8 that rs3817198 in the known breast cancer gene LSP1 
is associated with DA and also observed a genome-wide significant association for a weakly 
correlated SNP rs909116 (r-sq=0.24, D’=0.82). Both these SNPs have been associated with 
breast cancer risk and the recently published iCOGS19 analysis of breast cancer found that 
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rs3817198 is the SNP most strongly associated with breast cancer at the LSP1 locus. Large-
scale fine-mapping efforts are needed to pinpoint the causal variant(s).
SNP rs7289126 (TMEM184B) was associated with both DA and PD. A correlated SNP 
rs738322 (r-sq=0.34, D’=0.71) located in the PLA2G6 gene has previously been associated 
with cutaneous nevi20. Interestingly, two recent independent studies recently reported a link 
between cutaneous nevi and breast cancer21,22 and it is possible that this link can be partly 
explained through a shared genetic origin between cutaneous nevi and mammographic 
density.
The SNP rs17001868 (SGSM3/MKL1 region) is in moderate LD (r-sq=0.41, D’=0.76) with 
rs6001930 that has been previously associated with breast cancer19. We also observed 
several nearby SNPs located in the TNRC6B and MKL1 genes that were associated with DA. 
However, these SNPs did not remain significant after adjusting for rs17001868.
For NDA (n=7,600), multiple SNPs at 8p11.23 reached genome-wide significance in the 
discovery phase (Supplementary Figs. 5 and 6); this region has previously been associated 
with breast size11,23 (Table 1, Supplementary Figs. 8 and 9). Replication analysis 
(Supplementary Table 5) confirmed this region (top SNP rs7816345, combined 
P=2.4×10−23), and this SNP was also associated with PD on a genome-wide significant 
level.
For PD (n=7,916), the only two regions that reached genome-wide significance in the 
discovery stage were the previously identified ZNF3656 and 12q247 loci (Supplementary 
Figs. 10 and 11). Through replication analysis (Supplementary Table 6), we identified three 
new loci (P<5×10−8) that mapped to PRDM6, 8p11.23 and TMEM184B (Table 1, 
Supplementary Figs 12 and 13). rs7816345 (8p11.23) was also significantly associated with 
NDA and rs7289126 (TMEM184B) with DA on a genome-wide significance level. SNP 
rs186749 is located in PRDM6, a gene involved in regulation of endothelial cell 
proliferation, survival and differentiation. Interestingly, we observed a borderline 
association (P=2.6×10−7) between rs186749 and DA (Supplementary Table 4). We also 
observed two SNPs in ZNF365, rs10733779 and rs10509168, that reached genome-wide 
significance but their associations were attenuated when adjusting for the known PD SNP 
rs10995910. As with DA, analysis in larger datasets will be needed to assess the possibility 
of multiple independent SNPs in this region.
We used data from the ENCODE24 project to identify potential overlap between SNPs in 
regions associated with mammographic density phenotypes and regulatory elements in 
mammary tissue (Supplementary Table 7). We identified multiple SNPs in these regions that 
were in strong LD (r-sq≥0.8) with the lead SNPs and mapped to regulatory regions as 
defined by DNAse I hypersensitive site (DHS) or enhancer histone marks in mammary 
tissue for the ESR1, IGF1, TMEM184B, SGSM3/MKL1 and 8p11.23 regions. In particular, 
several SNPs including rs77275268 (proxy for rs12665607) in the ESR1 region map to a 
DHS in the breast MCF-7 and HMEC cell lines. SNP rs77275268 has previously been 
shown to disrupt a partially methylated CpG sequence within a known CTCF binding site25. 
Interestingly both rs77275268 and rs4820328 (proxy for rs7289126) in the TMEM184B 
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region are in regions that bind CTCF. CTCF is believed to play genome-wide role in 
transcriptional regulation and chromatic structure. In addition, rs4820328 also mapped to 
enhancer histone marks and DHS in HMEC cell lines. Based on these data, rs4820328 and 
rs77275268 are intriguing candidates for further follow up. We also identified SNPs in these 
regions that bind several proteins implicated in breast cancer including GATA3, ESR1, 
FOXA1, YY1, RAD21, SMC3, GR and EGR1. To explore potential function of identified 
SNPs further, we assessed their association with gene expression levels in adipose tissue and 
lymphoblastoid cell lines (LCL)26. The DA and PD SNP rs7289126 (TMEM184B) was 
associated with expression of MAFF and ANKRD54 in LCL (P<0.001) and BAIAP2L2 in 
adipose tissue (P<0.00001). rs17001868 (SGSM3/MKL1) was associated with SGSM3 
expression in both adipose tissue and LCL (P<0.0001). We also examined if any of these 
SNPs (or proxies) were associated with transcript levels in breast cancer tumors using data 
from The Cancer Genome Atlas27 (TCGA). We conducted both cis (within 1 Mb of the 
transcription start or end site) and trans (genome-wide) eQTL analysis. Although we did not 
identify any significant pathways in gene-set enrichment analysis, we identified some 
significant eQTLs with a raw p<0.00024 (Supplementary Table 9). Interestingly, rs4820328 
in the TMEM184B region that showed up in the ENCODE analysis was also associated with 
multiple transcript levels in TCGA.
To investigate if SNPs associated with mammographic density phenotypes are also 
associated with breast cancer, we accessed data from the GAME-ON (http://
gameon.dfci.harvard.edu) and iCOGS breast cancer meta-analysis based on 62,533 cases 
and 60,976 controls (Table 2). Eight out of nine SNPs were associated with breast cancer 
risk (P<0.05), four of which have already been reported to be associated with breast cancer 
on a genome-wide significance level (ESR1, ZNF365, LSP1 and SGSM3/MKL1)12–15,19,28. 
Four additional SNPs (PRDM6, 8p11.23, IGF1 and TMEM184B) were nominally associated 
with breast cancer (P<0.05, Table 2) and indicate potential new breast cancer susceptibility 
loci. Among the eight SNPs associated with both mammographic density phenotypes and 
breast cancer, six SNPs showed consistent direction between the mammographic density and 
breast cancer association, whereas SGSM3/MKL1 and 8p11.23 showed conflicting direction 
of associations with breast cancer in relation to the mammographic density association. We 
conducted SNP-breast cancer association analyses with and without adjusting for 
mammographic density (Supplementary Table 9) in up to 3,696 breast cancer cases and 
4,768 controls for whom we had mammographic density data on. We did not observe strong 
evidence that mammographic density mediates the SNP-breast cancer association, but we 
note that our low sample size limits our ability to draw conclusions from these analyses.
The SNPs identified here explain only a small fraction of the variance of DA (1.0%), NDA 
(0.4%) and PD (0.6%). We generated phenotype-specific genotype scores and estimated the 
difference in density associated with each density-increasing allele carried. The score-
specific differences per allele were 1.94 cm2 for DA, 8.58 cm2 for NDA and 0.77% for PD, 
respectively. It is noteworthy that two out of three SNPs associated with PD were associated 
with either DA or NDA and that there is overlap between our findings here and two recent 
GWAS of a correlated but distinct phenotype, breast size11,23. This was also partly reflected 
in our GWAS analyses (Supplementary Table 10, Supplementary Figs. 10–12).
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DISCUSSION
In this two-stage GWAS of mammographic density phenotypes we identified genome-wide 
significant loci for all three phenotypes investigated: dense area, non-dense area and percent 
density. Four of the identified regions are known breast cancer susceptibility loci, and four 
additional regions were found to be associated with breast cancer (P<0.05) in a large meta-
analysis. These four mammographic density SNPs represent putative novel breast cancer 
loci.
While the majority of density related SNPs we identified showed associations that were 
consistent in direction with breast cancer risk, there were two SNPs that were inconsistent. 
rs17001868 (SGSM3/MKL1) was strongly associated with both dense area and breast cancer 
risk but in opposite directions. Interestingly, there is accumulating data that MKL1 may 
have both tumor inhibiting and tumor promoting roles depending on the cellular context. 
Recently, it was shown that the MKL1 signaling pathway was activated in ER-cell lines and 
silenced in ER+ cell lines29. Additionally, the MKL1 breast cancer SNP has been shown to 
be associated with triple negative breast cancer30. rs17001868 has also been associated with 
SGSM3 (involved in signal transduction pathway) expression in both LCL and adipose 
tissue. While these data suggest that this SNP influences expression levels that may affect 
breast cancer risk, it is unclear how well these tissues represent expression in normal breast 
tissue. The differing effects of this pathway dependent on the ER status of the tissue29 
suggest that understanding the cellular environment is important. Although the underlying 
biology is still not well understood it suggests that it is possible that rs17001868 affects 
mammographic dense area and breast cancer risk through different mechanisms associated 
with different target genes. The majority of women included in our study were 
postmenopausal at the time of the mammogram. This single assessment of breast density 
will reflect both the formation of dense tissue early in life, as well as, influences such as age-
related and lactation related involution. The apparent opposing directions of this locus on 
dense area and breast cancer risk may suggest important biologic differences of the effect of 
this SNP on breast tissue and breast cancer risk by factors we are unable to assess in the 
current study (e.g, age, menopausal status). Similarly, rs7816345 was also associated with 
apparent opposing directions on non-dense area and breast cancer risk. Again, this may 
reflect true biologic differences over the life course. For example, it has been demonstrated 
that adiposity during early life is inversely associated with breast cancer31, while 
postmenopausal BMI is positively associated with breast cancer32.
There are some weaknesses with our study that should be mentioned. First, we used the 
HapMap project as imputation panel which prohibited us from assessing the contribution of 
rare variants. Future genetic studies of mammographic density phenotypes should use more 
dense imputation panels such as the 1000 Genomes33 that will provide a more complete 
coverage of the genome. Moreover, it is possible that the causal variant(s) within each 
mammographic density GWAS region was not captured here. Pin-pointing the causal 
variants will require not only denser genotyping and/or sequencing of these regions but also 
larger sample sizes. Another weakness with our study is that it was not designed or 
adequately powered to test if mammographic density mediates SNP effects on breast cancer. 
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Future large studies with both mammographic density and breast cancer data should assess 
such mediation effects.
In summary, we report multiple loci associated with mammographic density phenotypes. We 
identified six DA-specific loci of which five showed an association with breast cancer and 
one PD-specific locus also associated with breast cancer. We also report an additional locus 
associated with DA, PD and breast cancer risk as well as a locus associated with NDA, PD 
and breast cancer risk. These results confirm previous observations that mammographic 
density phenotypes and breast cancer risk share genetic origin and biological pathways34. 
Despite the smaller sample size in this mammographic density GWAS (N=7,916 in the 
discovery and N=10,379 in the replication phase) compared with recent large-scale breast 
cancer studies (N=22,627 in the discovery and N=87,170 in the replication phase)19, our 
ability to identify known as well as putative novel breast cancer loci by studying 
mammographic density phenotypes demonstrates the power of using quantitative 
intermediate phenotypes to discover new disease loci.
METHODS
Ethics Statement
Each study obtained informed consent from patients and had relevant ethics and institutional 
approvals from the following institutions. Brigham and Women’s Hospital (NHS), Harvard 
School of Public Health (NHSII), Norwich District Ethics Committee (EPIC-Norfolk), 
Karolinska Institutet (SASBAC), Mayo Clinic (MBCFS, MAYO VTE, MCOCS, MMHS, 
MCBCS), University Health Network, Toronto, Canada (TOR), Eastern Multicentre 
Research Ethics Committee (SIBS), Instituto de Salud Carlos III (DDM-Spain), University 
of Melbourne (AMDTDSS), University of Michigan and University of Maryland (OOA), 
The Cancer Council Victoria Ethic Commitee (MCCS), Friedrich-Alexander University 
Erlangen-Nuremberg (BBCC), NCI Special Studies Institutional Review Board (PBCS) and 
National Research Ethics Committee (NREC) East of England – Cambridge South 
(SEARCH).
Study design
We conducted a meta-analysis of twelve GWAS of mammographic density (Supplementary 
Note 1). For DA and NDA, we had GWAS data from eleven studies and for PD we had 
GWAS data from twelve studies. To follow up promising SNPs (p<0.0001) (Supplementary 
Tables 4–6), we conducted replication efforts using data from three different sources: 
iCOGS, iSelect and in silico look-ups in GWAS data. We assessed a total of 200 SNPs that 
showed suggestive associations with DA, NDA or PD for replication. We pursued 
replication of 114 SNPs that were included on the iCOGS19 array and genotyped additional 
86 SNPs in 3,832 women using a customized iSelect array. For the replication analysis, we 
also included data from the Old Order Amish (OOA, n=1,472) GWAS and for the DA 
analysis, the Australian MD Twins and Sisters Study (AMDTSS) GWAS (n=343).
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Genotyping, quality control and imputation
Study participants were genotyped on various genotyping platforms, and standard quality 
control filters for call rate, Hardy-Weinberg equilibrium p-value, and other measures were 
applied to exclude individuals and genotyped SNPs. To generate a common set of SNPs for 
meta-analysis, all studies were imputed to HapMap phase II (Supplementary Table 2). 
Imputed genotype dosage values (estimated reference allele count with a fractional value 
ranging from 0 to 2.0) were generated for approximately 2.5 million SNPs. SNPs with an 
imputation quality score <0.8 (as defined by the RSQR_HAT value in MACH, the 
PROPER_INFO in IMPUTE and the information content (INFO) measure in PLINK)) or a 
minor allele frequency <0.01 were excluded.
GWAS analysis
Primary association analysis was performed separately within each study. All studies except 
the Toronto/Melbourne (TOR) and AMDTSS used linear regression assuming an additive 
inheritance model. For imputed SNPs, the estimated number of effect alleles (ranging from 0 
to 2) was used as a covariate. To account for the family structure in Minnesota Breast 
Cancer Family Study (MBCFS) and Sisters in Breast Screening (SIBS), we used the 
“multic” package as implemented in R. Multic uses a linear mixed effects model, whereby 
the genetic relatedness among individuals is incorporated into the covariance structure of the 
random effects35,36. The relationships between subjects within the SIBS study were adjusted 
for using the mmscore option within ProbABEL, based on the estimated genomic kinship 
matrix37. The fixed effect is used for the tests of association and covariate adjustment. The 
TOR and AMDTSS used logistic regression where women in the 10% top percentile of 
percent mammographic density (TOR) or dense area (AMDTSS) were defined as “cases” 
and women in the bottom 10% percentile were defined as “controls”. As the included data 
from the Nurses’ Health Study (NHS) were generated using two different genotyping 
platforms, they were analyzed as two separate studies. Similarly, data from the Singapore 
and Sweden Breast Cancer Study (SASBAC) were obtained through two separate 
genotyping efforts and therefore analyzed separately. All studies adjusted their analysis for 
age and BMI. Additional study-specific adjustment factors are described in Supplementary 
Table 2. Study-specific genomic inflation factors ranged between 0.99 and 1.07.
Meta-analysis
Meta-analysis was based on summary statistics from the participating studies. For each SNP, 
we combined study-specific p-values and direction of association using the METAL 
software10. Weights were proportional to study-specific genomic inflation factors and 
sample size. To account for the extreme sampling scheme in the TOR study, we up-
weighted the study with a scale factor of 3.51. For a SNP to be considered in the meta-
analysis, we required genotyping data from at least 3,000 women. We used Cochran’s Q 
statistic to test for heterogeneity across studies.
Replication analysis
Candidate SNPs were followed up through replication genotyping and in silico look-ups. We 
obtained replication data from three separate sources: through the iCOGS genotyping19 
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effort, through a customized iSelect array and through look-ups in GWAS of 
mammographic density in the OOA and AMDTSS studies (Supplementary Note 2). In total, 
we successfully pursued and obtained replication data for 200 SNPs (Supplementary Tables 
4–6) selected based on their suggestive association (p<0.0001) with at least one of the 
density phenotypes. We also included the breast cancer SNPs rs10771399, rs1292011, 
rs909116 and rs2823093 since they were associated with at least one mammographic density 
phenotype at p<0.05. We extracted genotype data on 114 SNPs for 7,303 women for whom 
we had both iCOGS and mammographic density data. For SNPs that were not included on 
the iCOGS array but had a proxy (r-sq≥0.80) on the iCOGS array, we included the proxy 
instead. We also genotyped additional 86 SNPs in 3,878 women from the Nurses’ Health 
Study II (NHSII), the Mayo Mammography Health Study (MMHS), the Mayo Clinic Breast 
Cancer Study (MCBCS) and the Melbourne Collaborative Cohort Study (MCCS) using a 
customized iSelect array. We excluded subjects with call rates <95% (N=44) and two 
subjects (out of 204 included duplicates) that showed multiple discordances leaving 3,832 
subjects for analysis. Remaining duplicates had concordance >99%. In addition, we also 
included association results from the OOA (n=1,472) and AMDTSS (n=343 for the DA 
analysis) GWAS where available. To account for the extreme sampling scheme in 
AMDTSS, we up-weighted this study with a scale factor of 3.51. In total, our replication 
sample size for SNPs included on the iCOGS array was 9,118 women and the sample size 
for SNPs included on the iSelect 5,647 women.
Assessment of regulatory functions for identified SNPs
We used the ENCODE24 data to assess if any of the identified mammographic density SNPs 
or their proxies (r-sq≥0.8 in 1000 Genomes CEU population) are located in regulatory 
regions. Look-ups were made using the HaploReg38 and RegulomeDB39 software. We also 
investigated if identified mammographic density SNPs or their proxies were associated with 
gene expression in cis in adipose tissue and lymphoblastoid cell lines (LCL) in the 
MuTHER40 data by accessing the GeneVar26 database. To further explore the regulatory 
properties of the mammographic density SNPs, we conducted eQTL analyses on 
mammographic density SNPs and their proxies (r-sq≥0.8) using data from The Cancer 
Genome Atlas (TCGA). We identified eQTLs using BeQTL (manuscript under review, 
http://beqtl.org) that robustly assesses the association between SNP genotypes and mRNA 
transcript levels using linear regression with bootstrap. We assessed a total of 22 SNPs and a 
total of 18,985 transcripts among 608 estrogen receptor positive cases and 19,105 transcripts 
among 177 estrogen receptor negative cases. To robustly define the correlation between 
SNP genotype and gene expression level, the 95% confidence interval and median of the t-
statistic for the correlation coefficient were estimated via statistical bootstrap. For the 
bootstrap procedure, case resampling was performed N*log(N) times where N is the total 
number of cases. We computed p-values from the median t-statistic obtained in linear 
regression. Functional gene set analysis was performed using DAVID41,42 (http://
david.abcc.ncifcrf.gov/) for the set of transcripts achieving a raw p-value less than 0.00024 
in the eQTL analysis.
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Breast cancer association analysis
We looked up the association between mammographic density SNPs and breast cancer in the 
iCOGS19 + GAME-ON breast cancer GWAS meta-analysis. The GAME-ON meta-
analysis13,19,43,44 can be found at (http://gameon.dfci.harvard.edu) and is based on eleven 
breast cancer GWAS. In total, the reported breast cancer associations for the replicated 
mammographic density SNPs were based on 62,533 breast cancer cases and 60,976 controls. 
We conducted logistic regression analysis with and without adjustment for mammographic 
density including up to 3,696 breast cancer cases and 4,768 controls from the NHS, NHSII, 
MCBCS, MMHS, BBCC, SASBAC and MCCS studies.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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